Ramucirumab plus irinotecan / leucovorin / 5-FU versus ramucirumab plus paclitaxel in patients with advanced or metastatic adenocarcinoma of the stomach or gastroesophageal junction, who failed one prior line of palliative chemotherapy: the phase II/III RAMIRIS study (AIO-STO-0415).
FOLFIRI
Metastatic esophagogastric adenocarcinoma
Paclitaxel
Ramucirumab
Second line treatment
Journal
BMC cancer
ISSN: 1471-2407
Titre abrégé: BMC Cancer
Pays: England
ID NLM: 100967800
Informations de publication
Date de publication:
19 Jun 2023
19 Jun 2023
Historique:
received:
15
02
2022
accepted:
23
05
2023
medline:
21
6
2023
pubmed:
20
6
2023
entrez:
19
6
2023
Statut:
epublish
Résumé
Paclitaxel in combination with ramucirumab is the standard of care second-line therapy in gastro-esophageal adenocarcinoma (GEA). As the number of taxane pretreated patients in the perioperative or first-line setting is increasing, it is unknown whether these patients benefit from re-applying a taxane in using the combination of paclitaxel and ramucirumab. Furthermore, the rates of neurotoxicity with first-line FOLFOX or FLOT range from 30%-70%, making second-line taxane-containing therapy less suitable to a meaningful portion of patients. This patient group is likely to benefit from a taxane-free second-line chemotherapy regimen, such as FOLFIRI and ramucirumab (FOLFIRI-Ram). Therefore, the RAMIRIS phase III trial evaluates the effects of the regimen of FOLFIRI-Ram in the second-line treatment after a taxane-based chemotherapy in patients with advanced GEA. The RAMIRIS trial is a randomized, open-label, multicenter phase II/III study comparing treatment of FOLFIRI-Ram (arm A) with paclitaxel and ramucirumab (arm B). The Phase II is already closed with 111 enrolled patients. In the phase III, 318 taxane-pretreated patients with advanced GEA will be recruited and randomized 1:1 to FOLFIRI (5-FU 2400 mg/m The already completed RAMIRIS phase II demonstrated feasibility and efficacy of FOLFIRI-Ram. Especially docetaxel-pretreated patients seemed to markedly benefit from FOLFIRI-Ram, with favorable response- and PFS rates and lower toxicity. This offers a rationale for the phase III trial. If the RAMIRIS III trial transfers and confirms the results, they will affect the current treatment guidelines, recommending the combination therapy of FOLFIRI-Ram for taxane-pretreated patients with advanced GEA. NCT03081143 Date of registration: 13.11.2015.
Sections du résumé
BACKGROUND
BACKGROUND
Paclitaxel in combination with ramucirumab is the standard of care second-line therapy in gastro-esophageal adenocarcinoma (GEA). As the number of taxane pretreated patients in the perioperative or first-line setting is increasing, it is unknown whether these patients benefit from re-applying a taxane in using the combination of paclitaxel and ramucirumab. Furthermore, the rates of neurotoxicity with first-line FOLFOX or FLOT range from 30%-70%, making second-line taxane-containing therapy less suitable to a meaningful portion of patients. This patient group is likely to benefit from a taxane-free second-line chemotherapy regimen, such as FOLFIRI and ramucirumab (FOLFIRI-Ram). Therefore, the RAMIRIS phase III trial evaluates the effects of the regimen of FOLFIRI-Ram in the second-line treatment after a taxane-based chemotherapy in patients with advanced GEA.
METHODS
METHODS
The RAMIRIS trial is a randomized, open-label, multicenter phase II/III study comparing treatment of FOLFIRI-Ram (arm A) with paclitaxel and ramucirumab (arm B). The Phase II is already closed with 111 enrolled patients. In the phase III, 318 taxane-pretreated patients with advanced GEA will be recruited and randomized 1:1 to FOLFIRI (5-FU 2400 mg/m
DISCUSSION
CONCLUSIONS
The already completed RAMIRIS phase II demonstrated feasibility and efficacy of FOLFIRI-Ram. Especially docetaxel-pretreated patients seemed to markedly benefit from FOLFIRI-Ram, with favorable response- and PFS rates and lower toxicity. This offers a rationale for the phase III trial. If the RAMIRIS III trial transfers and confirms the results, they will affect the current treatment guidelines, recommending the combination therapy of FOLFIRI-Ram for taxane-pretreated patients with advanced GEA.
TRIAL REGISTRATION
BACKGROUND
NCT03081143 Date of registration: 13.11.2015.
Identifiants
pubmed: 37337155
doi: 10.1186/s12885-023-11004-z
pii: 10.1186/s12885-023-11004-z
pmc: PMC10278289
doi:
Substances chimiques
Camptothecin
XT3Z54Z28A
Fluorouracil
U3P01618RT
Irinotecan
7673326042
Leucovorin
Q573I9DVLP
Paclitaxel
P88XT4IS4D
taxane
1605-68-1
Banques de données
ClinicalTrials.gov
['NCT03081143']
Types de publication
Clinical Trial, Phase II
Clinical Trial, Phase III
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
561Informations de copyright
© 2023. The Author(s).
Références
J Gastrointest Oncol. 2018 Jun;9(3):560-572
pubmed: 29998022
Lancet. 2014 Jan 4;383(9911):31-39
pubmed: 24094768
J Clin Oncol. 2015 Nov 20;33(33):3874-9
pubmed: 26438119
World J Gastroenterol. 2016 Feb 28;22(8):2403-14
pubmed: 26937129
Gastric Cancer. 2019 Nov;22(6):1263-1273
pubmed: 30949777
Gastric Cancer. 2016 Apr;19(2):607-615
pubmed: 25792290
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593
N Engl J Med. 2012 May 31;366(22):2074-84
pubmed: 22646630
Lancet. 2010 Aug 28;376(9742):687-97
pubmed: 20728210
Nat Rev Clin Oncol. 2018 May;15(5):325-340
pubmed: 29508855
Ann Oncol. 2009 Oct;20(10):1667-73
pubmed: 19549707
J Gastrointest Oncol. 2021 Apr;12(2):906-909
pubmed: 34012679
Eur J Cancer. 2022 Apr;165:48-57
pubmed: 35202974
Gastric Cancer. 2018 Sep;21(5):738-744
pubmed: 29392573
Eur J Cancer. 2009 Jan;45(2):228-47
pubmed: 19097774
Ann Oncol. 2016 Sep;27(suppl 5):v38-v49
pubmed: 27664260
J Gastrointest Oncol. 2020 Apr;11(2):366-375
pubmed: 32399277
Jpn J Clin Oncol. 2008 Sep;38(9):589-95
pubmed: 18772169
J Clin Med. 2020 Aug 16;9(8):
pubmed: 32824326
Eur J Cancer. 2011 Oct;47(15):2306-14
pubmed: 21742485
ESMO Open. 2020 Jul;4(Suppl 2):
pubmed: 32719002
Oncologist. 2019 Apr;24(4):475-482
pubmed: 30470690
Lancet Oncol. 2015 May;16(5):499-508
pubmed: 25877855
CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33
pubmed: 10735013
Ann Oncol. 2008 Nov;19(11):1882-7
pubmed: 18669868
J Clin Oncol. 2010 Mar 20;28(9):1547-53
pubmed: 20159816
Ann Oncol. 2004 Jan;15(1):64-9
pubmed: 14679122
World J Surg Oncol. 2021 Sep 10;19(1):272
pubmed: 34507562
Cochrane Database Syst Rev. 2017 Aug 29;8:CD004064
pubmed: 28850174
J Clin Oncol. 2012 May 1;30(13):1513-8
pubmed: 22412140
Gastric Cancer. 2014 Apr;17(2):213-25
pubmed: 24048758
JAMA Oncol. 2017 May 01;3(5):620-627
pubmed: 27918764
Lancet Oncol. 2014 Oct;15(11):1224-35
pubmed: 25240821
Int J Cancer. 2020 Nov 1;147(9):2493-2502
pubmed: 32339253
Ann Oncol. 2016 Dec;27(12):2196-2203
pubmed: 27765757
JAMA Oncol. 2017 Sep 01;3(9):1237-1244
pubmed: 28448662
J Clin Oncol. 2008 Mar 20;26(9):1435-42
pubmed: 18349393
J Clin Oncol. 2011 Oct 20;29(30):3968-76
pubmed: 21844504
J Clin Oncol. 2006 Nov 1;24(31):4991-7
pubmed: 17075117
J Clin Oncol. 2014 Nov 1;32(31):3520-6
pubmed: 25287828
Lancet. 2019 May 11;393(10184):1948-1957
pubmed: 30982686